liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Gastrointestinal growth factors and pancreatic islet hormones during postoperative IGF-I supplementation in man
Linköping University, Department of Biomedicine and Surgery, Division of surgery. Linköping University, Faculty of Health Sciences.
Department of Biomedical Sciences, Creighton University School of Medicine, Omaha, Nebraska, USA.
Department of Biomedical Sciences, Creighton University School of Medicine, Omaha, Nebraska, USA and Department of Surgery, Karolinska Institute at Huddinge Hospital, Stockholm, Sweden.
Department of Surgery, Karolinska Institute at Huddinge Hospital, Stockholm, Sweden.
Show others and affiliations
2000 (English)In: Journal of Endocrinology, ISSN 0022-0795, E-ISSN 1479-6805, Vol. 167, no 2, 331-338 p.Article in journal (Refereed) Published
Abstract [en]

Insulin-like growth factor-I (IGF-I) has been demonstrated to exert a nitrogen sparing effect, both experimentally and in patients after abdominal surgery. IGF-I is a major mediator for the anabolic effects of growth hormone (GH). Whether elevated circulating IGF-I levels are the sole mediator of the anabolic effects following GH has not been clarified. IGF-I influences glucose metabolism, both through its own specific receptor and by activating the insulin receptor, and has also been proposed to influence pancreatic islet secretion directly. In the present study, the postoperative effects of IGF-I on plasma levels of other gastrointestinal and pancreatic islet hormones and growth factors were measured in patients after abdominal surgery. Fifteen patients who were candidates for large bowel resection were randomly divided into two groups: IGF-I-treated (n=8) and placebo-treated (n=7). The IGF-I group received daily two s.c. injections of human recombinant IGF-I (80 microg/kg body weight) for five days, beginning on the morning of the first postoperative day. The other group received placebo injections. Fasting plasma levels of gastrointestinal growth factors (epidermal growth factor, transforming growth factor-alpha, IGF-II), gastrointestinal hormones (gastrin, enteroglucagon, peptide YY), and islet hormones (insulin, islet amyloid polypeptide (IAPP) and pancreatic glucagon) were determined by RIA preoperatively and after five days of treatment. No significant effects of IGF-I on other growth factors or gastrointestinal hormones were seen. A marked increase in plasma insulin postoperatively compared with the preoperative levels (42+/-3 vs 61+/-5 pM, P<0.05) was seen in the placebo group, whereas the postoperative levels in the IGF-I-treated patients remained unchanged (44+/-3 vs 45+/-4 pM). A similar pattern was observed for IAPP and cortisol concentrations. No differences in glucagon concentrations were seen. In conclusion, these results suggest that IGF-I does not influence production of other gastrointestinal hormones thought to be involved in alimentary growth or pancreatic glucagon. In contrast, IGF-I caused a marked reduction of insulin and IAPP secretion. The inhibition of beta-cell secretion could be direct or, alternatively, could involve an improvement in postoperative insulin resistance, perhaps by reducing serum cortisol.

Place, publisher, year, edition, pages
2000. Vol. 167, no 2, 331-338 p.
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:liu:diva-49362DOI: 10.1677/joe.0.1670331ISI: 000167209400016OAI: oai:DiVA.org:liu-49362DiVA: diva2:270258
Available from: 2009-10-11 Created: 2009-10-11 Last updated: 2017-12-12
In thesis
1. Effects of IGF-I administration to the postoperative patient
Open this publication in new window or tab >>Effects of IGF-I administration to the postoperative patient
2005 (English)Licentiate thesis, comprehensive summary (Other academic)
Abstract [en]

n/a

Place, publisher, year, edition, pages
Linköping: Kopierat själv, 2005. 39 p.
Series
Linköping Studies in Health Sciences. Thesis, ISSN 1100-6013 ; 72
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-32756 (URN)18682 (Local ID)91-85299-18-9 (ISBN)18682 (Archive number)18682 (OAI)
Available from: 2009-10-09 Created: 2009-10-09 Last updated: 2013-09-20

Open Access in DiVA

No full text

Other links

Publisher's full text

Authority records BETA

Leinsköld, Ted

Search in DiVA

By author/editor
Leinsköld, Ted
By organisation
Division of surgeryFaculty of Health Sciences
In the same journal
Journal of Endocrinology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 38 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf